Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries

View ORCID ProfileMark J. Siedner, Christopher Alba, Kieran P. Fitzmaurice, Rebecca F. Gilbert, Justine A. Scott, Fatma M. Shebl, Andrea Ciaranello, Krishna P. Reddy, Kenneth A. Freedberg
doi: https://doi.org/10.1101/2021.04.28.21256237
Mark J. Siedner
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
3Africa Health Research Institute, KwaZulu-Natal, South Africa
4Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark J. Siedner
  • For correspondence: msiedner@mgh.harvard.edu
Christopher Alba
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kieran P. Fitzmaurice
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rebecca F. Gilbert
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Justine A. Scott
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fatma M. Shebl
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Ciaranello
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
4Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
5Harvard University Center for AIDS Research, Cambridge, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna P. Reddy
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
6Division of Pulmonary and Critical Care Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth A. Freedberg
1Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA
2Harvard Medical School, Boston, MA, USA
4Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
7Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
8Harvard T.H. Chan School of Public Health, Boston, MA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

Despite the advent of safe and highly effective COVID-19 vaccines1–4, pervasive inequities in global distribution persist5. In response, multinational partners have proposed programs to allocate vaccines to low- and middle-income countries (LMICs)6. Yet, there remains a substantial funding gap for such programs7. Further, the optimal vaccine supply is unknown and the cost-effectiveness of investments into global vaccination programs has not been described. We used a validated COVID-19 simulation model8 to project the health benefits and costs of reaching 20%-70% vaccine coverage in 91 LMICs. We show that funding 20% vaccine coverage over one year among 91 LMICs would prevent 294 million infections and 2 million deaths, with 26 million years of life saved at a cost of US$6.4 billion, for an incremental cost effectiveness ratio (ICER) of US$250/year of life saved (YLS). Increasing vaccine coverage up to 50% would prevent millions more infections and save hundreds of thousands of additional lives, with ICERs below US$8,000/YLS. Results were robust to variations in vaccine efficacy and hesitancy, but were more sensitive to assumptions about epidemic pace and vaccination costs. These results support efforts to fund vaccination programs in LMICs and complement arguments about health equity9, economic benefits10, and pandemic control11.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the National Institutes of Health (R37 AI058736-16S1). The findings and conclusions in this report are those of the authors and do not necessarily represent the official views of the US National Institutes of Health.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

No primary data collection or human subjects interactions was conducted as part of this analysis.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

There are no original data generated as part of this study. All data are derived from published or publicly available data and referenced as such. Code data will be made available to any requesting party by contacting the corresponding author.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted May 02, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
Mark J. Siedner, Christopher Alba, Kieran P. Fitzmaurice, Rebecca F. Gilbert, Justine A. Scott, Fatma M. Shebl, Andrea Ciaranello, Krishna P. Reddy, Kenneth A. Freedberg
medRxiv 2021.04.28.21256237; doi: https://doi.org/10.1101/2021.04.28.21256237
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries
Mark J. Siedner, Christopher Alba, Kieran P. Fitzmaurice, Rebecca F. Gilbert, Justine A. Scott, Fatma M. Shebl, Andrea Ciaranello, Krishna P. Reddy, Kenneth A. Freedberg
medRxiv 2021.04.28.21256237; doi: https://doi.org/10.1101/2021.04.28.21256237

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Health Economics
Subject Areas
All Articles
  • Addiction Medicine (174)
  • Allergy and Immunology (421)
  • Anesthesia (97)
  • Cardiovascular Medicine (901)
  • Dentistry and Oral Medicine (170)
  • Dermatology (102)
  • Emergency Medicine (257)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (407)
  • Epidemiology (8789)
  • Forensic Medicine (4)
  • Gastroenterology (405)
  • Genetic and Genomic Medicine (1863)
  • Geriatric Medicine (179)
  • Health Economics (388)
  • Health Informatics (1292)
  • Health Policy (644)
  • Health Systems and Quality Improvement (492)
  • Hematology (207)
  • HIV/AIDS (394)
  • Infectious Diseases (except HIV/AIDS) (10565)
  • Intensive Care and Critical Care Medicine (564)
  • Medical Education (193)
  • Medical Ethics (52)
  • Nephrology (218)
  • Neurology (1756)
  • Nursing (103)
  • Nutrition (266)
  • Obstetrics and Gynecology (343)
  • Occupational and Environmental Health (461)
  • Oncology (965)
  • Ophthalmology (283)
  • Orthopedics (107)
  • Otolaryngology (177)
  • Pain Medicine (118)
  • Palliative Medicine (43)
  • Pathology (264)
  • Pediatrics (557)
  • Pharmacology and Therapeutics (265)
  • Primary Care Research (219)
  • Psychiatry and Clinical Psychology (1845)
  • Public and Global Health (3986)
  • Radiology and Imaging (655)
  • Rehabilitation Medicine and Physical Therapy (344)
  • Respiratory Medicine (535)
  • Rheumatology (215)
  • Sexual and Reproductive Health (178)
  • Sports Medicine (166)
  • Surgery (197)
  • Toxicology (37)
  • Transplantation (106)
  • Urology (80)